consider
bodi
evid
exist
local
tissuebas
reninangiotensin
system
ra
angiotensin
ang
peptid
product
independ
circul
precursor
express
angiotensinogen
type
type
ang
ii
receptor
rat
human
lung
tissu
support
local
gener
ang
ii
membran
angiotensinconvert
enzym
ace
primarili
respons
convers
ang
ang
ii
circul
abundantli
express
vascular
endothelium
pulmonari
circul
ang
ii
modul
inflammatori
respons
promot
cytokin
product
express
endotheli
adhes
molecul
inflammatori
cell
migrat
epitheli
cell
apoptosi
oxid
stress
lung
fibroblast
growth
fibrosi
major
action
mediat
receptor
involv
complex
intracellular
signal
pathway
receptor
coupl
protein
stimul
multipl
signal
pathway
includ
mapkerk
rhorock
kinas
tyrosin
kinas
nfkb
aceang
receptor
axi
involv
mani
lung
diseas
anac
homolog
enzym
emerg
potent
neg
regul
ra
regul
ra
signal
reduc
ang
receptor
signal
activ
counterregulatori
angiotensin
ang
ma
receptor
pathway
protein
express
lung
mainli
vascular
endothelium
clara
cell
type
type
ii
alveolar
epitheli
cell
well
smooth
muscl
small
medium
vessel
mous
lung
ma
receptor
function
receptor
ang
present
thin
area
bronchial
epithelium
smooth
muscl
ma
receptor
pathway
often
serv
counterregul
proinflammatori
proprolif
profibrot
effect
aceang
receptor
pathway
pulmonari
hypertens
ph
disord
character
increas
mean
pulmonari
arteri
pressur
pap
mmhg
rest
assess
right
heart
catheter
rhc
term
pulmonari
arteri
hypertens
pah
describ
group
ph
patient
character
hemodynam
presenc
precapillari
ph
defin
pulmonari
arteri
wedg
pressur
pawp
mmhg
pulmonari
vascular
resist
pvr
wood
unit
wu
absenc
caus
precapillari
ph
ph
due
lung
diseas
chronic
thromboembol
pulmonari
hypertens
cteph
rare
diseas
hallmark
pah
vascular
remodel
process
increas
pvr
subsequ
right
ventricular
hypertrophi
prematur
death
regardless
underli
diseas
chronic
cor
pulmonal
associ
progress
clinic
deterior
poor
prognosi
case
incid
preval
pah
similar
usa
case
pah
per
million
inhabit
respect
uk
case
pah
per
million
inhabit
respect
clinic
classif
ph
categor
multipl
clinic
condit
five
group
accord
similar
clinic
present
patholog
find
hemodynam
characterist
treatment
strategi
diagnosi
ph
isbas
clinic
suspicion
establish
symptom
typic
induc
exert
short
breath
fatigu
weak
angina
syncop
symptomsat
rest
occur
advanc
circumst
abdomin
distens
ankl
edema
develop
progress
right
ventricl
rv
failur
diseas
caus
associ
ph
well
concurr
diseas
modifi
present
ph
advanc
basic
clinic
research
pah
led
improv
understand
diseas
pathogenesi
identif
novel
therapeut
target
aim
specif
therapi
ph
reduc
pvr
therebi
improv
rv
function
current
five
class
drug
appli
pah
endothelin
receptor
antagonist
era
prostanoid
phosphodiesteras
type
inhibitor
solubl
guanyl
cyclas
stimul
select
prostacyclin
receptor
agonist
despit
improv
patient
symptom
wellb
agent
mortal
rate
remain
high
surviv
year
new
therapi
need
target
altern
pathway
revers
pulmonari
vascular
remodel
inhibit
diseas
progress
improv
surviv
ra
intens
studi
altern
therapeut
target
larg
number
studi
shown
ra
importantli
involv
pah
pathophysiolog
lung
patient
pah
express
high
level
ace
intraacinar
arteri
suggest
local
increas
product
ang
ii
potent
pulmonari
vasoconstrictor
mitogen
action
may
contribut
process
pulmonari
vascular
remodel
ang
ii
also
capabl
induc
inflammatori
respons
vascular
wall
ang
ii
via
type
receptor
enhanc
product
reactiv
oxygen
speci
ro
stimul
nad
p
h
oxidas
vascular
wall
lead
endotheli
dysfunct
vascular
inflamm
stimul
redoxsensit
transcript
factor
nfkb
upregul
adhes
molecul
cytokin
chemokin
de
man
et
al
demonstr
increas
serum
level
renin
ang
ang
ii
correl
diseas
progress
mortal
patient
idiopath
pah
taken
togeth
find
indic
activ
role
ra
pulmonari
hypertens
process
abodi
evid
suggest
either
catalyt
product
ang
oppos
prolif
hypertroph
fibrot
effect
ang
ii
mani
organ
includ
lung
point
plausibl
protect
role
pah
ang
ii
appear
main
substrat
effect
hydrolyz
ang
protein
express
variou
human
organ
lung
express
mainli
vascular
endothelium
type
type
ii
alveolar
epitheli
cell
studi
demonstr
serum
decreas
patient
pah
due
congenit
heart
diseas
mean
pap
neg
correl
serum
level
similar
result
found
ang
suggest
decreas
ang
shift
balanc
ra
toward
aceang
receptor
axi
result
increas
vascular
remodel
fibrosi
pah
congenit
heart
diseas
patient
consist
find
sever
activ
diminazen
acetur
dize
xanthenon
xnt
e
ethylamino
hydroxymethyl
sulfonyloxi
resorcinolnaphthalein
report
variou
preclin
model
pah
recent
trial
hemn
et
al
assess
mechan
safeti
efficaci
singl
iv
infus
treatment
patient
idiopath
herit
pah
year
function
class
iiii
pah
patient
signific
decreas
activ
reflect
increas
ang
iiang
ratio
pah
patient
compar
control
treatment
pah
patient
decreas
ang
iiang
ratio
suggest
increas
activ
addit
level
superoxid
dismutas
protein
approxim
lower
pah
plasma
compar
control
treatment
signific
induct
plasma
protein
level
week
suggest
induct
enzymat
activ
compar
control
patient
pah
increas
level
cytokin
administr
suppress
could
detect
earli
hour
drug
administr
associ
sustain
antiinflammatori
effect
reduc
level
week
taken
togeth
data
show
treatment
reduc
marker
oxid
inflammatori
mediat
improv
balanc
aceang
receptor
ma
receptor
axi
ang
promot
thereleas
prostanoid
endotheli
cell
ec
smooth
muscl
cell
smc
releas
nitric
oxid
addit
ang
inhibit
prolifer
vascular
smc
ec
vitro
vivo
oppos
mitogen
effect
ang
ii
drug
inhibit
synthesi
ang
ii
ace
inhibitor
antagon
receptor
ang
ii
receptor
blocker
arb
shown
decreas
right
ventricular
hypertrophi
decreas
medial
thicken
peripher
muscular
small
pulmonari
arteri
hypox
anim
addit
ang
target
gene
transfer
protect
lung
model
pulmonari
hypertens
effect
ang
appear
associ
upregul
endotheli
nitric
oxid
synthas
eno
activ
via
akt
pathway
recent
zhang
et
al
show
phosphoryl
ampk
enhanc
stabil
increas
ang
nitric
oxid
synthas
eno
deriv
bioavail
endotheli
cell
shenoy
et
al
develop
plantbas
oral
deliveri
ang
protect
gastric
enzymat
degrad
facilit
longterm
storag
room
temperatur
fusion
transmucos
carrier
help
effect
system
absorpt
intestin
oral
deliveri
rat
fed
bioencapsul
ang
present
attenu
develop
monocrotalineinduc
ph
improv
cardiopulmonari
pathophysiolog
furthermor
revers
protocol
oral
ang
treatment
significantli
arrest
diseas
progress
along
improv
right
heart
function
decreas
pulmonari
vessel
wall
thick
addit
combin
therapi
ang
augment
benefici
effect
monocrotalineinduc
lung
injuri
accord
author
result
provid
proofofconcept
novel
lowcost
oral
ang
deliveri
system
use
transplastom
technolog
pulmonari
diseas
therapeut
microvesicl
deriv
mesenchym
stem
cell
msc
improv
outcom
pah
recent
liu
et
al
investig
whether
effect
mscderiv
microvesicl
pah
induc
monocrotalin
correl
ra
anim
treat
microvesicl
msc
notabl
attenu
pulmonari
arteri
pressur
revers
rv
hypertrophi
pulmonari
vessel
remodel
inflamm
score
collagen
fiber
volum
fraction
addit
mrna
lung
tissu
plasma
level
ang
upregul
anim
treat
msc
microvesicl
protect
effect
diminish
use
select
inhibitor
ma
receptor
fig
acut
respiratori
distress
syndrom
ard
lifethreaten
form
respiratori
failur
global
account
intens
care
unit
admiss
repres
three
million
patient
ard
annual
first
descript
date
year
ago
sinc
ard
redefin
sever
time
amelior
accuraci
clinic
diagnosi
last
one
berlin
definit
propos
three
categori
ard
base
sever
hypoxemia
time
acut
onset
origin
edema
chest
radiograph
comput
tomograph
ct
find
ard
result
wide
spectrum
differ
risk
factor
either
local
system
tabl
accord
origin
inflammatori
insult
ard
classifi
pulmonari
ard
ardsp
local
direct
lung
insult
extrapulmonari
ard
ardsexp
system
indirect
lung
injuri
import
clinic
differ
ardsp
ardsexp
patholog
radiographi
respiratori
mechan
respons
treatment
outcom
ard
remain
seriou
clinic
problem
main
treatment
support
form
mechan
ventil
howev
mechan
ventil
use
improperli
itcan
exacerb
tissu
damag
caus
ard
known
ventilatorinduc
lung
injuri
vili
date
intervent
demonstr
improv
clinic
outcom
ard
use
protect
ventilatori
strategi
use
low
tidal
volum
vt
mlkg
predict
bodi
weight
compar
tradit
appli
vt
mlkg
differ
anim
model
experiment
lung
injuri
use
investig
mechan
lung
injuri
committe
assembl
american
thorac
societi
at
publish
workshop
report
determin
main
featur
character
ard
anim
identifi
relev
measur
assess
featur
import
trait
includ
histolog
evid
tissu
injuri
alter
alveolar
capillari
barrier
presenc
inflammatori
respons
evid
physiolog
dysfunct
bodi
evid
demonstr
ra
involv
pathogenesi
ard
addit
cardiovascular
function
ang
ii
involv
inflammatori
fibrogen
process
lung
associ
ace
polymorph
suscept
progress
outcom
ard
demonstr
moreov
sever
studi
shown
inhibit
ard
receptor
blockad
inhibit
ang
ii
format
ace
protect
effect
ard
protect
effect
losartan
test
differ
model
ard
losartan
delay
onset
ard
wistar
rat
challeng
instil
bordetella
bronchiseptica
prevent
progress
deterior
ga
exchang
delay
mortal
infect
rat
sign
inflamm
thicken
alveolar
septa
mark
increas
cellular
domin
polymorphonuclear
leukocyt
much
less
evid
losartantr
rat
although
effect
associ
signific
inhibit
lungneutrophil
recruit
lung
bacteri
clearanc
impair
rather
significantli
improv
similar
result
found
irbesartan
differ
neither
ace
inhibitor
captopril
nonselect
peptid
inhibitor
ang
ii
receptor
saralasin
reproduc
effect
protect
effect
losartan
ard
attribut
least
part
nfkb
mapk
mechan
sepsisinduc
ard
use
cecal
ligat
punctur
clp
shen
et
al
demonstr
losartan
treatment
significantli
led
inhibit
lung
tissu
nfkb
activ
attenu
degrad
ikbalpha
inhibit
phosphoryl
extracellular
signalregul
kinas
cjun
ntermin
kinas
critic
pathway
cytokin
releas
similarli
result
raiden
et
al
show
losartan
delay
onset
ard
trigger
bacteri
infect
prevent
blood
ga
deterior
histopatholog
appear
ard
significantli
improv
surviv
sepsi
effect
captopril
losartan
also
test
fat
embol
fe
consequ
fat
embol
syndrom
fe
occur
trauma
surgeri
lead
seriou
pulmonari
injuri
includ
ard
death
reduct
pulmonari
inflamm
along
signific
decreas
intersept
edema
hemorrhag
patholog
chang
induc
fe
lumen
patenc
also
diminish
ra
inhibitor
extend
evid
involv
ra
syndrom
fletcher
et
al
demonstr
aliskiren
renin
inhibitor
protect
rat
lung
histopatholog
effect
fat
embol
ace
inhibit
blockad
receptor
favor
increas
ang
level
ard
imbal
occur
favor
increas
ace
activ
correl
lung
injuri
previou
studi
found
mrna
protein
enzymat
activ
sever
downregul
human
experiment
lung
tissu
injuri
decreas
express
importantli
involv
sever
acut
respiratori
syndrom
sar
pathogen
coronaviru
sarscov
trigger
sever
pneumonia
acut
often
lethal
lung
failur
kuba
et
al
demonstr
crucial
sarscov
receptor
vivo
sarscov
infect
spike
protein
sarscov
reduc
express
contribut
sever
lung
patholog
addit
inject
sarscov
spike
mice
worsen
acut
lung
failur
vivo
effect
associ
increas
ang
ii
lung
attenu
block
imai
et
al
report
lack
express
anim
precipit
ard
suggest
could
present
import
role
prevent
ard
ard
result
reduc
express
increas
ang
ii
product
anim
result
insult
elast
respiratori
system
well
pulmonari
edema
significantli
higher
sepsi
group
mainli
mice
addit
observ
thicken
alveolar
wall
edema
pulmonari
congest
infiltr
inflammatori
cell
hyalin
membran
sepsisinduc
mice
hour
observ
anim
group
aliv
anim
group
surviv
moreov
intraperiton
inject
recombin
human
protein
ard
induc
mice
prevent
increas
elast
respiratori
system
format
pulmonari
edema
contrast
mice
mice
genet
delet
ace
protect
acid
aspirationinduc
ard
inactiv
ace
anim
attenu
ard
likewis
pharmacolog
inhibit
genet
delet
receptor
significantli
attenu
lung
function
edema
format
hand
inactiv
receptor
aggrav
acut
lung
injuri
ali
recent
bone
marrowderiv
mesenchym
stem
cell
msc
overexpress
serv
vehicl
gene
therapi
lipopolysaccharid
lp
induc
ard
mice
msc
transduc
gene
lentivir
vector
infus
wildtyp
wt
knockout
mice
follow
lpsinduc
intratrach
lung
injuri
improv
lung
histopatholog
inflamm
decreas
neutrophil
count
balf
downregul
express
upregul
lung
addit
significantli
reduc
lung
edema
part
improv
lung
endotheli
permeabl
normal
lung
eno
express
increas
activ
decreas
ang
ii
increas
ang
lung
therebi
inhibit
detriment
effect
accumul
ang
ii
protect
mechan
experiment
ard
fulli
understood
regul
ra
signal
reduc
ang
receptor
signal
activ
counterregulatori
ang
ma
receptor
pathway
treatment
lentivir
packag
cdna
reduc
shrna
increas
ang
iiang
ratio
bronchoalveolar
lavag
lpsinduc
lung
injuri
inflammatori
respons
respons
associ
alter
phosphoryl
mapk
abolish
ma
receptor
antagonist
suggest
effect
mediat
ang
data
indic
protect
lung
injuri
via
increas
ang
turn
stimul
masmedi
signal
inhibit
activ
recent
studi
indic
earli
initi
therapi
experiment
ali
induc
oleic
acid
continu
drug
deliveri
benefici
optim
therapeut
effici
ang
treatment
cornerston
ard
manag
remain
mechan
ventil
howev
mechan
ventil
high
tidal
volum
caus
lung
hemorrhag
edema
activ
inflammatori
pathway
process
refer
ventilatorinduc
lung
injuri
vili
jiang
et
al
demonstr
increas
lung
ang
ii
level
induc
vili
deleteri
effect
attenu
captopril
ace
inhibitor
result
suggest
local
tissu
angiotensin
mediat
harm
event
vili
use
vili
model
high
tidal
volum
jerng
et
al
demonstr
lung
injuri
score
bronchoalveolar
lavag
fluid
protein
concentr
proinflammatori
cytokin
nfkb
activ
significantli
increas
highvolum
group
compar
control
addit
lung
ang
ii
mrna
level
angiotensinogen
receptor
also
significantli
increas
highvolum
group
pretreat
captopril
concomit
infus
losartan
highvolum
group
attenu
lung
injuri
inflamm
losartan
proteaseresist
cyclic
form
ang
show
similar
lung
protect
effect
losartan
caus
signific
decreas
blood
pressur
lpsexpos
ventil
anim
intraven
effect
ang
nonpeptid
agonist
evalu
ard
induc
intraven
inject
oleic
acid
ang
infus
minut
oleic
acid
administr
revers
lung
edema
attenu
increas
myeloperoxidas
activ
reflect
neutrophil
invas
addit
administr
ang
restor
arteri
pressur
kept
throughout
experiment
protocol
h
fall
rapidli
approxim
untreat
anim
ang
analog
also
prevent
decreas
pulmonari
vascular
resist
characterist
acut
phase
ard
ang
block
increas
concentr
bronchoalveolar
balf
effect
antagon
corrobor
result
imai
et
al
treatment
ibesartan
blocker
normal
system
blood
arteri
pressur
pulmonari
arteri
resist
wettodri
lung
weight
ratio
balf
protein
concentr
myeloperoxidas
activ
lung
tissu
benefici
effect
ibesartan
prevent
cotreat
either
system
pulmonari
hemodynam
thu
protect
effect
recombin
antagon
ali
may
relat
least
part
increas
format
ang
stimul
specif
receptor
signal
pathway
studi
effect
ang
test
two
murin
ard
model
ventilatorinduc
lung
acid
aspir
injuri
ang
revers
effect
model
ang
antiremodel
role
pulmonari
fibrosi
occour
ard
recent
zambelli
et
al
evalu
potenti
ang
attenu
ard
sever
lung
fibrosi
preclin
ard
model
author
evalu
ang
would
reduc
sever
earli
ard
induc
combin
insult
induc
unilater
acid
aspir
model
follow
high
stretch
mechan
ventil
ang
acut
infus
show
signific
improv
arteri
oxygen
inflammatori
respons
term
polymorphonuclear
recruit
alveoli
acut
ard
protocol
two
week
ang
infus
increas
blood
oxygen
satur
right
lung
treat
rat
show
signific
reduct
collagen
deposit
thu
inhibitori
effect
ang
inflammatori
cell
recruit
seen
acut
phase
may
relat
reduct
fibrosi
later
phase
benefici
effect
observ
jiang
et
al
jerng
et
al
may
relat
format
ang
use
captopril
andor
losartan
recent
khan
et
al
report
result
phase
ii
trial
examin
safeti
efficaci
use
recombin
human
year
old
patient
ard
mechan
ventil
less
h
use
twicedaili
dose
infus
mgkg
daysresult
decreas
plasma
ang
ii
associ
increas
ang
ang
remain
elev
h
also
trend
decreas
although
episod
hypotens
associ
infus
signific
improv
oxygen
observ
patient
ratio
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
index
sequenti
organ
failur
assessmentsofa
score
treat
placebo
group
observ
author
attribut
numer
factor
adequ
control
trial
howev
studi
reinforc
need
evalu
impact
ra
modul
pulmonari
hemodynam
marker
pulmonari
injuri
fig
epidemiolog
studi
show
asthma
current
common
chronic
diseas
children
major
caus
miss
day
school
adult
loss
work
day
addit
asthma
associ
signific
rate
mortal
larg
increas
incid
asthma
becom
major
global
health
problem
encourag
studi
aim
increas
knowledg
pathophysiolog
asthma
well
develop
new
treatment
improv
clinic
manag
diseas
mainli
meet
asthma
patient
respond
well
current
therapi
asthma
defin
revers
airway
obstruct
diseas
caus
airway
mucos
edema
inflamm
increas
mucu
secret
smooth
muscl
contract
airway
hyperreact
remodel
multipl
cell
multipl
mediat
play
crucial
pathophysiolog
role
inflammatori
respons
allerg
asthma
character
excess
product
ige
mast
cell
degranul
infiltr
eosinophil
lymphocyt
howev
recruit
activ
cell
depend
express
releas
sever
class
protein
cytokin
particularli
inflammatori
mediat
increas
influx
leukocyt
activ
surviv
eosinophil
posit
correl
asthma
sever
failur
resolv
inflammatori
process
caus
persist
inflamm
consequ
tissu
destruct
loss
pulmonari
function
experiment
clinic
evid
indic
activ
pulmonari
ra
involv
pathophysiolog
allerg
pulmonari
diseas
especi
inappropri
increas
angiotensin
ii
ang
ii
howev
ang
ma
receptor
axi
recogn
counterregulatori
peptid
system
within
ra
exhibit
antiinflammatori
effect
prevent
inappropri
remodel
differ
pathophysiolog
state
asthma
show
effect
treatment
ang
three
main
chang
observ
chronic
asthma
inflamm
pulmonari
remodel
bronchial
hyperespons
experiment
studi
tri
clear
aspect
pathophysiolog
asthma
mimick
human
diseas
classic
includ
two
phase
sensit
challeng
sensit
tradit
perform
intraperiton
subcutan
rout
challeng
allergen
perform
aerosol
intranas
intratrach
instil
sensibil
increas
ige
level
circul
induc
sign
inflamm
pulmonari
remodel
ige
bind
receptor
eosinophil
mast
cell
basophil
challeng
occur
allergen
allergen
provok
antigenicantibodi
reaction
induc
degranul
cell
degranul
releas
inflammatori
mediat
initi
propag
process
ovalbumin
ova
wide
use
allergen
promot
intens
allerg
lung
inflamm
addit
common
speci
studi
last
two
decad
mice
particularli
balbc
experiment
model
acut
asthma
balbc
mice
ang
treatment
result
inhibit
ovainduc
increas
total
cell
count
eosinophil
lymphocyt
neutrophil
ang
also
significantli
reduc
ovainduc
perivascular
peribronchi
inflamm
fig
moreov
ang
attenu
ovainduc
increas
phosphoryl
erk
suggest
ang
could
mediat
antiinflammatori
pathway
allerg
asthma
chronic
allerg
lung
inflamm
administr
ang
synthet
analog
ave
ma
receptor
agonist
decreas
inflammatori
cell
infiltr
peribronchi
perivascular
alveolar
region
lung
furthermor
ang
treatment
decreas
chemokin
cytokin
gmcsf
ige
two
signal
pathway
associ
asthma
possibl
jnk
pathway
altogeth
result
suggest
ang
treatment
decreas
chemokin
cytokin
essenti
initi
mainten
inflammatori
process
well
import
migrat
eosinophil
site
injuri
reduct
apoptosi
effect
associ
inhibit
pathway
demonstr
genet
ma
defici
increas
chronic
allerg
pulmonari
inflamm
fvbn
mice
genet
delet
ma
receptor
subject
model
chronic
allerg
lung
inflamm
present
signific
increas
number
eosinophil
balf
inflammatori
cell
infiltr
lung
furthermor
increas
phosphoryl
proinflammatori
cytokin
chemokin
lung
mice
asthmat
genet
delet
ma
receptor
thu
ma
receptorinduc
effect
import
counterbalanc
mechan
ra
attenu
inflammatori
process
asthma
moreov
impair
ang
ma
receptor
pathway
may
lead
deterior
pathophysiolog
asthma
defect
apoptosi
eosinophil
main
leukocyt
pathogenesi
asthma
delay
remov
lead
lung
damag
loss
pulmonari
function
due
failur
resolut
inflamm
recent
demonstr
novel
action
ang
resolut
allerg
lung
inflamm
balbc
mice
sensit
challeng
ova
treat
ang
peak
inflammatori
process
treatment
ang
reduc
accumul
eosinophil
lung
induc
apoptosi
addit
ang
treatment
reduc
phosphoryl
intracellular
signal
pathway
associ
cytokin
product
leukocyt
surviv
increas
apoptosi
leukocyt
clearanc
macrophag
essenti
event
promot
resolut
inflamm
ang
treatment
increas
clearanc
apoptot
cell
macrophag
result
ad
import
criteria
establish
ang
endogen
proresolut
mediat
unregul
prolong
inflammatori
respons
lung
lead
tissu
damag
pulmonari
remodel
consequ
compromis
lung
function
isevid
lung
inflamm
remodel
asthmat
patient
experiment
model
asthma
restrict
airway
extend
parenchyma
pulmonari
vessel
addit
leukocyt
migrat
lung
structur
cell
airway
epithelium
smooth
muscl
cell
secret
varieti
inflammatori
mediat
extracellular
matrix
protein
particip
immunomodul
airway
remodel
asthma
model
chronic
ovasensit
challeng
mice
increas
deposit
collagen
fibr
airway
wall
increas
express
collagen
iii
lung
along
thicken
alveolar
wall
smooth
muscl
arteriol
addit
ovamic
show
right
ventricular
hypertrophi
probabl
due
function
structur
adapt
respons
chronic
pulmonari
arteri
pressur
overload
lung
section
mice
challeng
intranas
ova
four
consecut
day
ova
show
sever
perivascular
peribronchi
fibrosi
mark
goblet
cell
hypermetaplasia
suggest
airway
remodel
contrast
lung
section
ovachalleng
mice
treat
ang
decreas
perivascular
peribronchi
fibrosi
goblet
cell
hypermetaplasia
studi
mice
sensit
challeng
ova
three
time
per
week
four
week
ova
mice
exhibit
significantli
greater
thicken
inflamm
alveolar
wall
epitheli
thick
collagen
deposit
airway
lung
parenchyma
increas
addit
ova
induc
increas
mrna
express
collagen
collagen
iii
howev
ovasensit
challeng
anim
treat
ang
present
reduc
inflamm
interalveolar
space
normal
appear
alveolar
lumen
reduc
epitheli
thick
furthermor
ovasensit
challeng
mice
treat
ang
present
mark
reduct
collagen
deposit
airway
wall
lung
parenchyma
mrna
express
collagen
iii
fig
model
chronic
asthma
mice
lack
ma
receptor
induc
intens
degre
lung
inflamm
remodel
mice
strain
fvbn
less
sensit
experiment
model
asthma
inde
fvbnwt
wildtyp
mice
present
attenu
respons
ova
challeng
compar
respons
observ
balbc
mice
subject
protocol
howev
delet
ma
receptor
induc
worsen
develop
chronic
allerg
lung
inflamm
mice
data
show
impair
ang
ma
receptor
pathway
may
lead
deterior
pathophysiolog
asthma
recent
studi
show
treatment
ang
peak
inflammatori
process
induc
resolut
eosinophil
inflamm
experiment
model
asthma
balbc
mice
sensit
challeng
ovalbumin
treat
ang
h
last
ova
challeng
inclus
ang
oligosaccharid
caviti
protect
peptid
passag
gastrointestin
tract
resolut
inflamm
activ
process
allow
cessat
inflamm
reestablish
tissu
homeostasi
therefor
oral
treatment
ang
promot
prevent
excess
traffick
eosinophil
lung
shutdown
intracellular
signal
molecul
associ
cytokin
product
eosinophil
surviv
apoptosi
recruit
eosinophil
promot
clearanc
apoptot
leukocyt
ie
efferocytosi
effect
induc
return
pulmonari
homeostasi
decreas
extracellular
matrix
accumul
great
reduct
collagen
iii
gene
express
lung
data
acceler
research
effort
develop
new
ang
base
pharmacolog
strategi
control
prevent
treat
chronic
inflammationrel
diseas
asthma
thu
observ
ang
effect
oral
rout
provid
clinic
benefit
treatment
allerg
asthma
better
toler
nebul
standard
drug
act
sistem
reduc
overal
inflamm
optim
health
patient
pulmonari
fibrosi
pf
fatal
lung
diseas
unknown
caus
diseas
character
progress
scar
lung
tissu
accompani
fibroblast
prolifer
sudden
onset
lung
parenchyma
thicken
alveolar
septa
hyperplasia
type
ii
pneumocyt
pii
myofibroblast
caus
narrow
airway
lead
loss
lung
function
decreas
qualiti
life
theestim
preval
pf
around
case
per
peopl
reach
individu
per
peopl
age
year
treatment
forpf
antiinflammatori
immunosuppress
antifibrot
agent
shown
promis
result
abat
progress
diseas
improv
qualiti
life
therefor
becom
essenti
better
understand
diseas
pathophysiolog
identifi
novel
therapeut
targetsag
treatment
pf
bleomycin
blm
use
describ
method
caus
pf
rodent
chemotherapeut
use
treatment
sever
neoplasia
challeng
blm
intratrach
administr
caus
lung
lesion
parenchyma
inflamm
lesion
alveolar
epitheli
cell
reactiv
hyperplasia
activ
fibroblast
myofibroblast
differenti
pulmonari
fibrosi
addit
presenc
ph
secondari
fibrot
lung
diseas
call
cor
pulmonal
indic
poor
prognosi
compromis
cardiac
function
studi
demonstr
ang
receptor
requir
pathogenesi
experiment
lung
fibrosi
ang
ii
number
profibrot
effect
lung
parenchym
induct
growth
factor
mesenchym
cell
extracellular
matrix
deposit
product
cytokin
increas
motil
lung
fibroblast
recent
evid
show
counterregulatori
molecul
ang
product
act
antifibrot
pulmonari
surviv
factor
shenoy
et
al
show
endotrach
instil
bleomycin
evok
sever
fibrot
respons
character
accumul
interstiti
lung
collagen
addit
increas
lung
mrna
level
import
cytokin
play
key
role
fibrogenesi
transform
growth
also
observ
collagen
deposit
significantli
decreas
overexpress
ang
furthermor
studi
detect
pulmonari
hypertens
ph
right
ventricular
hypertrophi
rvh
bleomycin
administr
howev
treatment
ang
prevent
develop
ph
rvh
treatment
ang
overexpress
present
similar
benefici
effect
possibl
mediat
via
gener
ang
conceiv
protect
effect
ang
heart
may
secondari
reduct
lung
fibrosi
meng
et
al
investig
whether
upregul
ma
axi
protect
blminduc
pulmonari
fibrosi
inhibit
mitogenactiv
protein
kinas
mapk
pathway
experiment
protocol
male
wistar
rat
submit
pf
blm
andor
angii
result
show
ang
regul
balanc
ra
axi
toward
ma
axi
blmtreat
anim
present
characterist
histolog
chang
lung
tissu
includ
area
inflammatori
infiltr
thicken
alveolar
wall
increas
interstiti
collagen
deposit
fibroblast
appear
chronic
infus
ang
result
protect
effect
lung
fibrosi
furthermor
treatment
ang
protect
blm
angiiinduc
inflamm
extracellular
matrix
ecm
accumul
inhibit
signal
pathway
result
suggest
treatment
ang
decreas
activ
mapk
pathway
jnk
crucial
lung
fibrogenesi
studi
vitroshow
human
fetal
cell
pretreat
compound
block
activ
receptor
ma
mapk
exposur
ang
ii
ang
human
fetal
cell
infect
lentivirusmedi
exposur
ang
ii
ang
lentivirusmedi
inhibit
ang
iiinduc
pathway
therebi
attenu
inflamm
product
could
revers
ma
receptor
antagonist
ang
inhibit
ang
iiinduc
lung
fibroblast
apoptot
resist
via
inhibit
pathway
activ
mitochondri
apoptot
pathway
well
known
addit
mapk
activ
reactiv
oxygen
speci
ro
gener
nadph
initi
lung
fibrosi
ro
gener
play
relev
role
lung
fibrosi
recent
studi
suggest
nadph
oxidas
nox
key
sourc
ro
fibrot
lung
mediat
fibroblast
function
lung
fibrosi
process
stress
addit
mice
genet
delet
protect
blminduc
pulmonari
fibrosi
meng
et
al
show
ro
caus
activ
aceang
receptor
axi
contribut
develop
angii
blminduc
lung
fibrosi
fibroblast
migrat
synthesi
ang
treatmentprotect
blminduc
pulmonari
fibrosi
shift
balanc
ra
toward
ma
axi
inhibit
gener
ro
addit
ang
protect
blm
ang
iiinduc
lung
fibroblast
migrat
ecm
accumul
inhibit
result
suggest
ma
axi
could
novel
pharmacolog
antioxid
target
lung
fibrosi
induc
ang
iimedi
ro
